 SAN DIEGO, Aug. 30, 2021 PRNewswire -- Poseida Therapeutics, Inc. Nasdaq: PSTX, a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the U.S. Food and Drug Administration FDA has cleared its Investigational New Drug IND application for P-BCMA-ALLO1, the Companys first fully allogeneic CAR-T product candidate for patients with relapsedrefractory multiple myeloma. Poseida announces FDA clearance of IND for its first fully allogeneic CAR-T therapy for patients with multiple myeloma. 